• 1
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J. 1995; 311: 899909.
  • 3
    D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus nonplatinum-based chemotherapy in non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005; 23: 29262936.
  • 4
    Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85: 384388.
  • 5
    Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993; 85: 388394.
  • 6
    Bonomi P, Kim K, Kusler J, et al. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Huntingt). 1997; 11: 910.
  • 7
    Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol. 1994; 12: 26822686.
  • 8
    Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998; 16: 153158.
  • 9
    Akerley W, Choy H, Safran H, et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol. 1997; 24: S12–10S12–13.
  • 10
    Akerley W, Herndon J, Egorin M, et al. Weekly high-dose paclitaxel in advanced lung carcinoma: a phase II trial with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003; 97: 24802486.
  • 11
    Chang AY, Rubins J, Asbury R, Boros L, Hui LF. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol. 2001; 4( Suppl 14): 1013.
  • 12
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491498.
  • 13
    Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 1997; 8: 525529.
  • 14
    Lara PNJr., Gumerlock PH, Mack PC, et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004; 6: 102107.
  • 15
    Aggarwal L, Akerley W, Wingate P, et al. Weekly paclitaxel—effect on platelets in patients with NSCLC and in patients with prostate cancer and thrombocytopenia [#202]. Proc Am Soc Clin Oncol. 1998; 17: 52a.
  • 16
    Pertusini E, Ratajczak J, Majka M, et al. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood. 2001; 97: 638644.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002; 20: 35783585.
  • 19
    Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol. 2003; 21: 39093917.
  • 20
    Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer (Amster). 2002; 38: 7377.
  • 21
    Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol. 2002; 25: 509512.
  • 22
    Popa IE, Stewart K, Smith FP, et al. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer. 2002; 95: 17141719.
  • 23
    Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose escalating study. Eur J Cancer. 2000; 36: 23292334.